KRAS and colonic neoplasm: Cost-effectiveness comparison of chemotherapy + anti-EGFR mAb vs. chemotherapy + bevacizumab in (a) KRAS wild-type (b) pan-RAS wild-type and (c) pan-RAS wild-type left-sided colonic tumor.